Literature DB >> 15635022

Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

F Damond1, F Brun-Vezinet, S Matheron, G Peytavin, P Campa, S Pueyo, F Mammano, S Lastere, I Farfara, F Simon, G Chene, D Descamps.   

Abstract

We described the baseline polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene from 94 treatment-naive patients and the longitudinal follow-up of 17 protease inhibitor-treated patients. Compared to the HIV-2 consensus sequences, baseline polymorphism involved 47 positions. Substitutions selected under treatment were observed at positions corresponding to HIV-1 resistance mutations as well as at positions of currently unknown impact on HIV-1.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15635022      PMCID： PMC540186          DOI： 10.1128/JCM.43.1.484-487.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  17 in total

1.  Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.

Authors:  B Rodés; A Holguín; V Soriano; M Dourana; K Mansinho; F Antunes; J González-Lahoz
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Drug Resistance Mutations in HIV-1.

Authors:  Richard T. D'Aquila; Jonathan M. Schapiro; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Lisa M. Demeter; Robert M. Grant; Victoria A. Johnson; Daniel R. Kuritzkes; Clive Loveday; Robert W. Shafer; Douglas D. Richman
Journal:  Top HIV Med       Date:  2002 Nov-Dec

3.  Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast.

Authors:  D Pieniazek; D Ellenberger; L M Janini; A C Ramos; J Nkengasong; M Sassan-Morokro; D J Hu; I M Coulibally; E Ekpini; C Bandea; A Tanuri; A E Greenberg; S Z Wiktor; M A Rayfield
Journal:  AIDS Res Hum Retroviruses       Date:  1999-04-10       Impact factor: 2.205

4.  HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.

Authors:  Danuta Pieniazek; Mark Rayfield; Dale J Hu; John N Nkengasong; Vincent Soriano; Walid Heneine; Clement Zeh; Simon M Agwale; Charles Wambebe; Liliana Odama; Stefan Z Wiktor
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

5.  HIV-1 and HIV-2 AIDS in African patients living in Paris.

Authors:  S Matheron; G Mendoza-Sassi; F Simon; R Olivares; J P Coulaud; F Brun-Vezinet
Journal:  AIDS       Date:  1997-06       Impact factor: 4.177

6.  Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load.

Authors:  V Soriano; P Gomes; W Heneine; A Holguín; M Doruana; R Antunes; K Mansinho; W M Switzer; C Araujo; V Shanmugam; H Lourenço; J González-Lahoz; F Antunes
Journal:  J Med Virol       Date:  2000-05       Impact factor: 2.327

7.  Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy.

Authors:  M E van der Ende; C Guillon; P H Boers; T D Ly; R A Gruters; A D Osterhaus; M Schutten
Journal:  J Acquir Immune Defic Syndr       Date:  2000-09-01       Impact factor: 3.731

8.  Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.

Authors:  Sophie Matheron; Sophie Pueyo; Florence Damond; François Simon; Annie Leprêtre; Pauline Campa; Roger Salamon; Genevieve Chêne; Françoise Brun-Vezinet
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

9.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

10.  Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.

Authors:  P Colson; M Henry; C Tourres; D Lozachmeur; H Gallais; J A Gastaut; J Moreau; C Tamalet
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948
View more
  24 in total

1.  Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Authors:  Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

Review 2.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.

Authors:  Dana N Raugi; Robert A Smith; Selly Ba; Macoumba Toure; Fatou Traore; Fatima Sall; Charlotte Pan; Lindsey Blankenship; Alexandra Montano; Julia Olson; Ndeye Mery Dia Badiane; James I Mullins; Nancy B Kiviat; Stephen E Hawes; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

4.  The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

5.  Improving HIV-2 detection by a combination of serological and nucleic acid amplification test assays.

Authors:  Anna Rita Ciccaglione; Michela Miceli; Giulio Pisani; Roberto Bruni; Paola Iudicone; Angela Costantino; Michele Equestre; Elena Tritarelli; Cinzia Marcantonio; Paola Tataseo; Maria Cristina Marazzi; Susanna Ceffa; Giovanna Paturzo; Anna Maria Doro Altan; Massimo Magnano San Lio; Sandro Mancinelli; Massimo Ciccozzi; Alessandra Lo Presti; Giovanni Rezza; Leonardo Palombi
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

6.  Clinical evaluation of BioPlex 2200 HIV Ag-Ab, an automated screening method providing discrete detection of HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody.

Authors:  Maud Salmona; Severine Delarue; Constance Delaugerre; François Simon; Sarah Maylin
Journal:  J Clin Microbiol       Date:  2013-10-23       Impact factor: 5.948

7.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Authors:  Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

8.  Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

Authors:  Sabelle Jallow; Abraham Alabi; Ramu Sarge-Njie; Kevin Peterson; Hilton Whittle; Tumani Corrah; Assan Jaye; Matthew Cotten; Guido Vanham; Samuel J McConkey; Sarah Rowland-Jones; Wouter Janssens
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

9.  HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal.

Authors:  Geoffrey S Gottlieb; Stephen E Hawes; Kim G Wong; Dana N Raugi; Habibatou D Agne; Cathy W Critchlow; Nancy B Kiviat; Papa Salif Sow
Journal:  AIDS Res Hum Retroviruses       Date:  2008-06       Impact factor: 2.205

10.  Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease.

Authors:  Andrey Y Kovalevsky; John M Louis; Annie Aniana; Arun K Ghosh; Irene T Weber
Journal:  J Mol Biol       Date:  2008-09-20       Impact factor: 5.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.